Honest framing matters here: substantial human safety data for CJC-1295 comes from a single small early-phase study of the with-DAC form, so the side-effect picture is drawn from limited trial data and community reports rather than a robust record. Commonly reported effects are local or related to fluid shifts, such as injection-site irritation, flushing, water retention, and tingling.[1]
Reviewed for accuracy · Last reviewed July 8, 2026The published human study of the with-DAC form reported no serious adverse events in that small setting. Because CJC-1295 raises the body's own growth hormone and IGF-1, GH-class considerations such as changes in insulin sensitivity or blood sugar are plausible but are not well characterized at these doses. The without-DAC form (mod GRF 1-29) has no dedicated human safety trial, so its profile is inferred rather than established.
Rotating injection sites and watching for persistent numbness or spreading redness are the practical basics. Signs of an allergic reaction are a reason to seek medical attention rather than wait.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.